Bazedoxifene (Wyeth)

Current Opinion in Investigational Drugs

Volumn 5, Issue 10, 2004, Pages 1086-1093

  Gruber, Christian ^a   Gruber, Doris ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

BAZEDOXIFENE; ESTROGEN RECEPTOR; INDOLE DERIVATIVE; SELECTIVE ESTROGEN RECEPTOR MODULATOR;

ANIMAL; CLINICAL TRIAL; FEMALE; HUMAN; METABOLISM; POSTMENOPAUSE OSTEOPOROSIS; REVIEW; STRUCTURE ACTIVITY RELATION; TREATMENT OUTCOME;

ANIMALS; CLINICAL TRIALS; FEMALE; HUMANS; INDOLES; OSTEOPOROSIS, POSTMENOPAUSAL; RECEPTORS, ESTROGEN; SELECTIVE ESTROGEN RECEPTOR MODULATORS; STRUCTURE-ACTIVITY RELATIONSHIP; TREATMENT OUTCOME;

EID: 16644368991     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (53)

1. 174352 Ligand and Wyeth-Ayerst initiate sex steroid/women's health collaboration. Up to $44 million in research support and equity or convertible to equity loans. Ligand Pharmaceuticals PRESS RELEASE 1994 September 07
2. 177058 Annual report - Ligand Pharmaceuticals - 1994. Ligand Pharmaceuticals Inc ANNUAL REPORT 1994 December 31
3. 209597 Ligand and Wyeth-Ayerst add compound series, expand collaboration into osteoporosis. Ligand Pharmaceuticals PRESS RELEASE 1996 May 30
4. 282314 Ligand announces Wyeth-Ayerst submitted IND for osteoporosis compound. Ligand Pharmaceuticals Inc PRESS RELEASE 1998 March 26
5. 301293 Drug pipeline. Ligand Pharmaceuticals Inc FORM 10-K 1998 March 31
6. 360128 US drug industry RX insight - American Home Products Corp. LEHMAN BROTHERS INC 2000 January 18 71
7. 385483 American Society for Bone and Mineral Research 22nd Annual Meeting, Toronto, Canada, 22-26 September 2000. Blake S IDDB MEETING REPORT 2000 September 22-26
8. 385899 American Society for Bone and Mineral Research 22nd Annual Meeting (Part III), Osteoporosis Drugs, Toronto, Canada, 22-26 September 2000. Morii H IDDB MEETING REPORT 2000 September 22-26
9. 395411 Ligand receives milestone for TSE-424. Ligand Pharmaceuticals Inc PRESS RELEASE 2001 January 08
10. 408940 Investor relations: Presentations - Deutsche Bank Health Care Conference. American Home Products Corp COMPANY WORLD WIDE WEB SITE 2001 May 09
11. 410070 American Home Products Corporation's 2001 Analyst Meeting. American Home Products Corp COMPANY PRESENTATION 2001 May 16
12. 410449 Design, synthesis and preclinical characterization of novel, highly selective indole estrogens. Miller CP, Collini MD, Tran BD, Harris HA, Kharode YP, Marzolf JT, Moran RA, Henderson RA, Bender RHW, Unwalla RJ, Greenberger LM et al J MED CHEM 2001 44 11 1654-1657
13. 413288 Ligand reaps cash reward as AHP moves TSE-424 into phase III. Ligand Pharmaceuticals Inc PRESS RELEASE 2001 June 21
14. 418901 American Home Products sales model. LEHMAN BROTHERS INC 2001 June 19
15. 420809 Pharmaceutical Desk Reference: Global equities research US -Our models of the major US pharma companies. LEHMAN BROTHERS INC 2001 August
16. 423079 Form 10-K: Ligand Pharmaceuticals Inc. Ligand Pharmaceuticals Inc FORM 10-K 2000 December 31
17. 426718 Equity research, pharmaceuticals: Company comment -American Home Products. Krensavage M, Bailey M RAYMOND JAMES & ASSOCIATES INC 2001 October 01
18. 428972 CIBC World Markets Health Care Conference. American Home Products Corp COMPANY PRESENTATION 2001 November 06
19. 429708 Credit Suisse First Boston Health Care Conference. American Home Products Corp COMPANY PRESENTATION 2001 November 14
20. 441412 TSE-424, a novel tissue selective estrogen, reduces biochemical indices of bone metabolism in a dose related fashion. Ronkin S, Clarke L, Boudes P, Constantine G J BONE MINER RES 2001 16 1 S41
21. 443491 Presentations: SG Cowen Health Care Conference - March 12, 2002. Wyeth COMPANY PRESENTATION 2002 March 12
22. 444030 Annual report 2001: Wyeth. Wyeth ANNUAL REPORT 2002 March 14
23. 467310 Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women's Health Initiative randomized controlled trial. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM et al J AM MED ASSOC 2002 288 3 321-333
24. 473188 Lack of clinically relevant pharmacokinetic interaction between bazedoxifene and ibuprofen. Baird SJ, McKeand WE, Ermer JC, Patat AA, Garcia Quetglas E CLIN PHARMACOL THER 2002 71 2 24-27
25. 481801 FDA approves Wyeth's new low dose Prempro lower hormone dose with efficacy comparable to the leading hormone therapy. Wyeth Pharmaceuticals PRESS RELEASE 2003 March 13
26. 495370 Now available - PREMPRO 0.45 mg/1.5 mg - a new low dose hormone therapy option. Wyeth Ayerst Pharmaceuticals Inc PRESS RELEASE 2003 July 01
27. 502705 Developing a SERM: Stringent preclinical selection criteria leading to an acceptable candidate (WAY-140424) for clinical evaluation. Komm BS, Lyttle CR ANN NY ACAD SCI 2001 949 317-326
28. 502969 An improved synthetic route to analogues of the new SERMs WAY-138923 and WAY-140424. Santilli AA, Koko MC, Viet AQ ACS 2003 226 ORGN 132
29. 519151 Bazedoxifene acetate metabolic disposition in healthy, postmenopausal women. Chandrasekaran A, Ermer J, McKeand W, Lee H, DeMaio W, Kotake A, Sullivan P, Orczyk G, Scatina J CLIN PHARMACOL THER 2003 73 2 47
30. 519153 Bazedoxifene acetate dose proportionality in healthy, postmenopausal women. Ermer J, McKeand W, Sullivan P, Parker V, Orczyk G CLIN PHARMACOL THER 2003 73 2 46
31. 519156 Absolute/relative bioavailability of bazedoxifene acetate in healthy postmenopausal women. Patat A, McKeand W, Baird Bellaire S, Ermer J, LeCoz F CLIN PHARMACOL THER 2003 73 2 43
32. 519158 Maintenance of therapeutic effects of hPTH in ovariectomized rats with established osteopenia: Evaluation of bazedoxifene, raloxifene and ethinyl estradiol. Kharode YP, Marzolf JT, Bodine PVN, Komm BS, Bex FJ J BONE MINER RES 2002 17 Suppl 1 S209
33. 523405 2-Phenylindoles. Relationship between structure, estrogen receptor affinity, and mammary tumor inhibiting activity in the rat. von Angerer E, Prekajac J, Strohmeier J J MED CHEM 1984 27 11 1439-1447
34. 523406 The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen. Shiau AK, Barstad D, Loria PM, Cheng L, Kushner PJ, Agard DA, Greene GL CELL 1998 95 7 927-937
35. 531460 Ligand Pharmaceuticals - An emerging high-growth Bio-Pharmaceutical company. Ligand Pharmaceuticals Inc COMPANY PRESENTATION 2004 March 15
36. 531786 Treatment of postmenopausal osteoporosis. Delmas PD LANCET 2002 359 9322 2018-2026
37. 531787 Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-Year results from the MORE trial. Multiple outcomes of raloxifene evaluation. Cauley JA, Norton L, Lippman ME, Eckert S, Krueger KA, Purdie DW, Farrerons J, Karasik A, Mellstrom D, Ng KW, Stepan JJ et al BREAST CANCER RES TREAT 2001 65 2 125-134
38. 531789 Raloxifene improves endothelial dysfunction in hypertension by reduced oxidative stress and enhanced nitric oxide production. Wassmann S, Laufs U, Stamenkovic D, Linz W, Stasch JP, Ahlbory K, Rosen R, Bohm M, Nickenig G CIRCULATION 2002 105 17 2083-2091
39. 533392 Annual report 2003 - Wyeth. Wyeth ANNUAL REPORT 2004 March 04
40. 541677 Wyeth initiates desvenlafaxine phase III trials for hot flushes. Wyeth PRESS RELEASE 2004 June 02
41. 541985 Analyst meeting - R&D update 2004. Wyeth COMPANY PRESENTATION 2004 June 02
42. 550018 Hormone and nonhormone therapy for the maintenance of postmenopausal health: The need for randomized controlled trials of estrogen and raloxifene. Barrett-Connor E, Wenger NK, Grady D, Mosca L, Collins P, Kornitzer M, Cox DA, Moscarelli E, Anderson PW J WOMENS HEALTH 1998 7 7 839-847
43. 550697 Raloxifene: A review of its use in postmenopausal osteoporosis. Clemett D, Spencer CM DRUGS 2000 60 2 379-411
44. 550698 Adverse events reported by postmenopausal women in controlled trials with raloxifene. Davies GC, Huster WJ, Lu Y, Plouffe L Jr, Lakshmanan M OBSTET GYNECOL 1999 93 4 558-565
45. 554143 Form 10-K: Ligand Pharmaceuticals Inc. Ligand Pharmaceuticals Inc FORM 10-K 1999 March 31
46. 554603 Long-term treatment of lasofoxifene preserves bone mass and bone strength and does not adversely affect the uterus in ovariectomized rats. Ke HZ, Foley GL, Simmons HA, Shen V, Thompson DD ENDOCRINOLOGY 2004 145 4 1996-2005
47. 554605 Lasofoxifene (CP-336,156) protects against the age-related changes in bone mass, bone strength, and total serum cholesterol in intact aged male rats. Ke HZ, Qi H, Chidsey-Frink KL, Crawford DT, Thompson DD J BONE MINER RES 2001 16 4 765-773
48. 554607 The evolution of tamoxifen therapy in breast cancer: Selective oestrogen-receptor modulators and downregulators. O'Regan RM, Jordan VC LANCET ONCOL 2002 3 4 207-214
49. 554610 A randomized double-blind trial to compare the efficacy of teriparatide [recombinant human parathyroid hormone (1-34)] with alendronate in postmenopausal women with osteoporosis. Body JJ, Gaich GA, Scheele WH, Kulkarni PM, Miller PD, Peretz A, Dore RK, Correa-Rotter R, Papaioannou A, Cumming DC, Hodsman AB J CLIN ENDOCRINOL METAB 2002 87 10 4528-4535
50. 555369 Bazedoxifene + conjugated estrogens: A balanced combination to provide optimal 'estrogenic' safety and efficacy. Komm BS, Kharode Y, Bodine P, Bex F AM SOC BONE MINER RES 2003 25 Abs SU385
51. 555370 Combining a SERM with conjugated estrogens (CE) to improve the SERM profile: Not all SERMs may succeed. Komm BS, Kharode Y, Bodine P, Bex F AM SOC BONE MINER RES 2003 25 Abs SU386
52. 555373 Comparison of the effects of bazedoxifene, raloxifene, lasofoxifene and risedronate co-treatment on hPTH-induced reversal of established osteopenia in ovariectomized rats. Kharode YP, Green PD, Marzolf JT, Murrils RJ, Bodine PVN, Komm BS, Bex FJ AM SOC BONE MINER RES 2003 25 Abs SU387
53. 555701 Wyeth (WYE). Grofik G CITIGROUP SMITH BARNEY 2004 July 15